Business
Neurotrope Announces Corporate Update and Reports Second Quarter 2019 Financial Results
NEW YORK, Aug. 5, 2019 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for
About this update from Nexttrip, Inc.
[{"type":"text","content":"NEW YORK, Aug. 5, 2019 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today provided an update on clinical and corporate developments, including its ongoing confirmatory Phase 2 study of Bryostatin-1 in moderate to severe AD, and announced financial results for the second quarter ended June 30, 2019.\n\"The promising data from our previous exploratory Phase 2 trial showed significant improvements in Severe Impairment Battery (SIB) scores for patients in the 20µg Bryostatin-1 dose group not on memantine, an NMDA antagonist. These results may indicate a potential reversal of disease progression in patients with moderate to severe AD, suggesting the potential to translate Bryostatin's neurorestorative properties into the clinic. We look forward to reporting top-line data from our confirmatory Phase 2 study during the third quarter of 2019, and to moving bryostatin forward in the clinic,\" stated Dr. Charles S. Ryan, Neurotrope's Chief Executive Officer.\nDr. Daniel Alkon, Neurotrope's President and Chief Scientific Officer, stated: \"Our confirmatory Phase 2 trial is based on compelling clinical data that was recently published in the Journal of Alzheimer's Disease.1 Bryostatin regulates the NMDA receptor through PKC activation. Thus, the concurrent use of an NMDA antagonist, which inhibits activity at the receptor, may block the beneficial effects of bryostatin a potential eliminated from the current trial design. Moreover, the consistency observed in 94% of those patients not taking memantine further supports our current study and underscores the transformative potential of bryostatin as a treatment for AD.\"\nDr. Marwan Sabbagh, Director of the Cleveland Clinic Lou Ruvo Center for Brain Health and member of Neurotrope's Scientific Advisory Board, noted: \"Bryostatin has a novel mechanism of action, restoring synaptic networks, with some encouraging data published earlier this year. I believe that positive results from the current study would be a significant advancement for patients with moderate to severe Alzheimer's Disease. I look looking forward to seeing the results of the Confirmatory Phase 2 study in the near future.\"\nClinical Development Highlights\nOn July 15, 2019, Neurotrope con...